Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BIOTECH & TECHNOLOGY INVESTING *UNDERVALUED*{T/A F/A & V} -- Ignore unavailable to you. Want to Upgrade?

To: BRAVEHEART who wrote (40)	1/30/1999 5:32:00 PM
From: QuietWon	Read Replies (1) \| Respond to of 423

Finally, a thoughtful, insightful, and top it off well articulated post. I don;t know VION, so thank you. And a great move ! I took a look at VION's website and could not find the type of info I found for IMCL and ONXX. Not having that info, I can't at the moment make that comparison. However, I can say, IMCL having 100% of patients with more than 50% tumour reduction, and 88% having 100% regression that must be excellent! No side effects reported - the whole idea behind this non-chemo generation of drugs is to localize, thus having reduced chances of side effects. In summary, take the assump that side effects pretty much the same in IMCL, ONXX, VION , then IMCL is pretty darn impressive. Certainly, IMCL beats ONXX hands down.

To: BRAVEHEART who wrote (40)	1/31/1999 1:21:00 PM
From: CPAMarty	Respond to of 423

have been asking around and will post once i have obtained info comparing VION, IMCL and ONXX prospects/data on side effects etc. RE:insiders However, it appears FWIW that a director sold 8000 shrs of VION the first week in December '98 at 4.16/share. No recent insider sales of ONXX, however during first half of '98 there was some significant selling at the $7 level - i know that circumstances could have dramatically changed since then. As previously posted there is a strong insider buying pattern at IMCL